84 results match your criteria: "centre d'addictovigilance[Affiliation]"
Therapie
October 2024
Inserm U 1058, Pathogenesis and Control of Chronic Infections (PCCI), centre d'addictovigilance, Montpellier University Hospital, 34000 Montpellier, France.
France has several monitoring systems that form the foundation of its health safety surveillance. This system is designed for the early detection of signals and their swift into an action system that enables timely, appropriate, and effective interventions to protect public health. These signals are considered alerts when sufficiently validated after an initial risk assessment and if they represent a potential threat to public health, necessitating an appropriate response.
View Article and Find Full Text PDFTherapie
November 2024
Service de pharmacologie médicale et toxicologie, centre d'addictovigilance, CHU de Montpellier, 34295 Montpellier, France; Pathogenesis and Control of Chronic Infections (PCCI), Inserm U 1058, 34000 Montpellier, France. Electronic address:
From 2019, in the United States and Europe, the synthetic opioid market has diversified with the appearance of the 2-benzylbenzimidazole family, commonly named "nitazenes". In vitro studies show that these synthetic opioids have much higher affinities on μ-opioid receptors: 100 times more than morphine, and slightly higher than fentanyl for isotonitazene, increasing the risk of overdose. In south of France, isotonitazene (IZN) was identified for the first time in March 2023.
View Article and Find Full Text PDFTherapie
October 2024
Centre d'évaluation et de traitement de la douleur, Toulouse University Hospital, 31059 Toulouse, France.
Aim: Patients with chronic non-cancer pain are referred to pain centres to improve their pain treatment. The discontinuation of pain medications in case of poor efficacy can be difficult to accept for patients, particularly opioid analgesics. Previous research has described that from the patients' perspective, the psychological relief of a negative effect of chronic pain and withdrawal symptoms of prescription opioids represent drivers of persistent use and first stage of opioid use disorder, despite insufficient pain relief.
View Article and Find Full Text PDFBMC Public Health
April 2024
Centre d'Evaluation et d'Information sur la Pharmacodépendance-Addictovigilance (CEIP-A), Service de Pharmacologie Clinique, Nantes Université, CHU Nantes, F-44000, Nantes, France.
Background: Chronic use of cannabis is associated with an increased risk of psychosocial, mental and physical health impairments. Sociohealth institutions reach a very limited proportion of cannabis users in need of treatment. Using data collected from festival attendees, this study aimed to estimate the prevalence of dependent cannabis users and to characterize cannabis dependence.
View Article and Find Full Text PDFClin Toxicol (Phila)
February 2024
Centre antipoison de Lyon, SHUPT, Hospices Civils de Lyon, Lyon, France.
Introduction: Ammonia solution (ammonium hydroxide) is used to convert cocaine hydrochloride to freebase cocaine. Due to its causticity, unintentional exposure to ammonia in a substance use context can result in injury. The objective of this study was to describe the characteristics of unintentional oral and buccal ammonia solution exposure in a substance use context.
View Article and Find Full Text PDFFundam Clin Pharmacol
April 2024
INSERM, BPH, University of Bordeaux, Bordeaux, France.
Background: The combination dextropropoxyphene/paracetamol (DXP/P) was the most prescribed opioid analgesic until its withdrawal in 2011.
Objectives: This study investigated dispensations of analgesics in chronic users of DXP/P during the 18 months following its withdrawal.
Methods: A cross-sectional study repeated yearly was conducted by using the French reimbursement database from 2006 to 2015.
Public Health
October 2023
Service de Pharmacologie Médicale, CHU de Bordeauxx, Centre de Pharmacovigilance de Bordeaux, F-33000 Bordeaux, France; University Bordeaux, INSERM, BPH, U1219, CHU de Bordeaux, F-33000 Bordeaux, France; Service de Pharmacologie Médicale, Centre d'Addictovigilance, CHU de Bordeaux, F-33000 Bordeaux, France. Electronic address:
Objectives: At the beginning of the COVID-19 pandemic, the French Addictovigilance Network drew attention to the need to facilitate access to methadone while ensuring its safe use, in order to avoid the occurrence of overdoses and deaths. The objectives of the study were to assess the impact of the lockdowns on the incidence of methadone-use-related hospitalisations (MUHs) and describe the characteristics of patients and hospitalisations.
Study Design: An interrupted time series using the unobserved components model was performed to predict the monthly incidence of MUHs in 2020 on the basis of previous years' data and compared with MUHs observed.
Therapie
June 2024
Centre d'addictovigilance, service de pharmacologie clinique, hôpital de la Timone, Assistance publique-Hôpitaux de Marseille, Aix-Marseille université, institut de neurosciences des systèmes, Inserm UMR1106, 13005 Marseille, France.
Introduction: Due to the risk of overdoses increase especially with methadone, a reinforced monitoring has been set up by the French Addictovigilance Network following the first lockdown related to coronavirus disease 2019 (COVID-19). In this context, we managed a specific study to analyze overdoses related to methadone in 2020 compared to 2019.
Material And Methods: We analyzed methadone-related overdoses which occurred in 2019 and 2020 from two sources: DRAMES program (deaths with toxicological analysis) and the French pharmacovigilance database (BNPV) (overdoses that did not lead to death).
Int J Drug Policy
August 2023
Univ. Bordeaux, INSERM, BPH, U1219, Bordeaux F-33000, France; Hospital Charles Perrens, Bordeaux F-33000, France.
Backgrounds: The Covid-19 pandemic offered a unique opportunity to investigate trends in hospitalizations related to psychoactive substance intoxication, since the usual health burden of social use at parties and gatherings was likely to be decreased during lockdowns and curfew periods. Since young adults are the main users of psychoactive substances for experimental and recreational purposes, this study identified and compared hospitalization trends in young adults and adults over 30 years old.
Methods: This national cohort study was conducted using the French hospital discharge database.
Front Public Health
May 2023
Nantes Université, CHU Nantes, Service de Pharmacologie Clinique - Centre d'Evaluation et d'Information sur la Pharmacodépendance-Addictovigilance, Nantes, France.
Introduction: Nitrous oxide has become over the last few years a public health problem in many countries. France has a dedicated health monitoring system dedicated to the surveillance of the abuse, dependence and consequences associated with the use of psychoactive substances coordinated by the French National Agency for the Safety of Medicines and Health Products.We present the French national survey of nitrous oxide.
View Article and Find Full Text PDFArch Womens Ment Health
June 2023
Centre d'addictovigilance de Paris, Hôpital Fernand Widal APHP, Paris, France.
J Neurol
April 2023
U1172, CHU de Lille, Centre de référence des maladies neuromusculaires Nord, Est, Ile-de-France, Service de neurologie, Lille, France.
Toxics
December 2022
CHU de Lille, Service Hormonologie Métabolisme Nutrition Oncologie, F-59000 Lille, France.
In the last few years, there has been an increase in the recreational use of nitrous oxide (N2O), which can lead to neurological symptoms such as sensory or motor disorders. The literature links these symptoms to a functional inactivation of vitamin B12 by oxidation of its cobalt ion, which prevents the vitamin B12 from acting as a cofactor for methionine synthase. Thus, demyelination related to methionine deficiency could be responsible for the neurological disorders associated with N2O consumption, including the combined sclerosis of the spinal cord.
View Article and Find Full Text PDFInt J Environ Res Public Health
November 2022
CHU Clermont-Ferrand, Service de Pharmacologie Médicale, Centre d'Addictovigilance et Pharmacovigilance, Centre Evaluation et Traitement de la Douleur, Inserm, Neuro-Dol, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France.
Analgesic opioid (AO) misuse by patients ranges from 0% to 50%. General practitioners are the first prescribers of AO. Our objective was to validate the Prescription Opioid Misuse Index (POMI) in primary care.
View Article and Find Full Text PDFAnn Pharm Fr
May 2023
CHU de Lille, service hormonologie métabolisme nutrition oncologie, 59000 Lille, France. Electronic address:
Therapie
March 2023
Service de pharmacologie médicale et clinique, centre d'addictovigilance (CEIP-A), CHU de Toulouse - UFR santé, université de Toulouse, 31000 Toulouse, France.
Context: Substance use disorders during pregnancy are associated with antenatal, neonatal and long-term adverse drug reactions in children. The aim of this study was to describe, using data from OPPIDUM survey, the evolution of illicit substance use or diverted prescription drug use among pregnant women visiting French addiction care centres from 2005 to 2018.
Material And Method: The current study focused on women of childbearing age (15-44years old) identified as pregnant, and included in the OPPIDUM survey from 2005 to 2018.
Therapie
March 2023
Service de pharmacologie médicale et clinique, centre d'addictovigilance (CEIP-A), CHU de Toulouse-UFR santé, université de Toulouse, 31000 Toulouse, France. Electronic address:
Epidemiology of substance use disorders and their complications is driven by a male predominance, and women, even if they are more and more prevalent, are never specifically represented in studies in the field. Apart from the time of pregnancy, which in itself requires specific prevention, treatment and follow-up, the importance of the sex of women in the complications of substance abuse is neglected. To illustrate, we described some characteristics of women identified in the addictovigilance information system in France and Europe, related to drug use disorders (both for illicit substances and medications).
View Article and Find Full Text PDFTherapie
May 2023
Université Bordeaux, Inserm, BPH, U1219, 33000 Bordeaux, France; CHU de Bordeaux, centre d'addictovigilance de Bordeaux et Départements d'Outre-Mer, service de pharmacologie médicale, 33000 Bordeaux, France. Electronic address:
Objectives: Over the last 10 years, the use of an unknown drug called "chimique" has emerged, among adolescents and young adults in precarious situations in Mayotte Island. To date, the exact composition of "chimique" is still poorly documented, but seizures made on the Island at the same time indicated that it would be mainly composed of synthetic cannabinoids receptor agonists (SCRAs). The objective of this study was to identify which substances, among those consumed under the name of "chimique", leading to hospital admissions.
View Article and Find Full Text PDFTherapie
May 2023
Service de pharmacologie médicale, CHU de Bordeaux, centre de pharmacovigilance de Bordeaux, 33000 Bordeaux, France; Université de Bordeaux, Inserm, BPH, U1219, 33000 Bordeaux, France.
Rev Med Interne
July 2022
Centre antipoison de Paris - Fédération de toxicologie (FeTox), hôpital Fernand-Widal, AP-HP, 75010 Paris, France; Inserm, UMRS-1144, Faculté de pharmacie, 75006 Paris, France; UFR de médecine, université de Paris, 75010 Paris, France. Electronic address:
Introduction: Recreational use of nitrous oxide (NO) is increasing in Western countries, including France. During the COVID-19 pandemic, some authors warned that recreational NO use could increase further as the supply of illicit drugs was impacted by various containment measures.
Methods: We retrospectively analyzed NO exposures reported to the Paris Poison Control Center (France) from 2010/01/01 to 2021/04/15.
Can J Anaesth
August 2022
Service de Pharmacologie médicale, Centres Addictovigilance et Pharmacovigilance, Centre Evaluation et Traitement de la Douleur, Service Psychiatrie-Addictologie, Université Clermont Auvergne, CHU Clermont-Ferrand, Inserm, Neuro-Dol, Clermont-Ferrand, France.
Purpose: The Prescription Opioid Misuse Index scale (POMI) is a brief questionnaire used to assess opioid prescription misuse. In view of the increase in the prescription of opioid analgesics for chronic noncancer pain (CNCP), this tool is particularly useful during medical consultations to screen opioid misuse in patients using opioids. We sought to generate and validate a French-European translation of the POMI.
View Article and Find Full Text PDFFood Chem Toxicol
April 2022
Inserm, Univ. Lille EA 7364 RADEME, CHU Lille, Centre de Biologie Pathologie Génétique, UF Métabolisme Général et Maladies Rares, F-59000, Lille, France. Electronic address:
Nitrous oxide (NO) toxicity is a concern common to several medical fields. Here, retrospective study of four NO abuses with neurological signs in the emergency practice provides a preliminary basis for a metabolic Discussion/Review. This latter highlights NO abuse as pathology of DNA/RNA/protein methylations, for instance consistent with impairments of protein arginine methyltransferases involved in myelinogenesis and myelopathy in patients.
View Article and Find Full Text PDFFundam Clin Pharmacol
October 2022
Department of Medical Pharmacology, Centre d'addictovigilance de Bordeaux, Bordeaux, France.
Little is known about psychoactive substance use in students, apart from tobacco, alcohol, and cannabis. This study investigated the prevalence of substance use and overlap between various psychoactive substances in students. This cross-sectional study was conducted in 10 066 students included in the i-Share cohort between January 1, 2015, and December 31, 2017.
View Article and Find Full Text PDFRev Med Interne
March 2022
Service d'hormonologie, métabolisme, nutrition, oncologie, CHU de Lille, 59000 Lille, France.
J Psychoactive Drugs
October 2022
Département de Pharmacologie Médicale Et Toxicologie, Centre d'Addictovigilance, Chu Montpellier, Univ Montpellier, Montpellier, France.
Pregabalin is indicated for the treatment of partial epilepsy, generalized anxiety disorder, and neuropathic pain. The first reports on pregabalin use disorder have been published in Europe in 2010 and notified to the French Addictovigilance Network (FAN) in 2011. The management of pregabalin use disorder is challenging due to the risks associated with the abrupt withdrawal and lack of guidelines.
View Article and Find Full Text PDF